Cepheid Company Profile (NASDAQ:CPHD)

About Cepheid (NASDAQ:CPHD)

Cepheid logoCepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Diagnostic & Testing Equipment
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CPHD
  • CUSIP: 15670R10
  • Web: www.cepheid.com
Average Prices:
  • 50 Day Moving Avg: $52.75
  • 200 Day Moving Avg: $38.36
  • 52 Week Range: $25.09 - $53.91
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 53.48
  • P/E Growth: 0.00
  • Net Margins: -6.88%
  • Return on Equity: -11.54%
  • Return on Assets: -5.18%
  • Debt-to-Equity Ratio: 0.76%
  • Current Ratio: 4.30%
  • Quick Ratio: 3.24%
  • Average Volume: 2.11 million shs.
  • Beta: 0.67

Frequently Asked Questions for Cepheid (NASDAQ:CPHD)

What is Cepheid's stock symbol?

Cepheid trades on the NASDAQ under the ticker symbol "CPHD."

How were Cepheid's earnings last quarter?

Cepheid (NASDAQ:CPHD) issued its earnings results on Thursday, July, 28th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.14) by $0.19. The business had revenue of $146 million for the quarter, compared to the consensus estimate of $145.82 million. Cepheid had a negative return on equity of 11.54% and a negative net margin of 6.88%. The company's revenue was up 10.2% compared to the same quarter last year. During the same period last year, the business posted ($0.06) EPS. View Cepheid's Earnings History.

Who are some of Cepheid's key competitors?

How do I buy Cepheid stock?

Shares of Cepheid can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cepheid's stock price today?

One share of Cepheid stock can currently be purchased for approximately $52.95.

MarketBeat Community Rating for Cepheid (NASDAQ CPHD)
Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  396 (Vote Underperform)
Total Votes:  785
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cepheid (NASDAQ:CPHD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A
Consensus Price Target History for Cepheid (NASDAQ:CPHD)
Price Target History for Cepheid (NASDAQ:CPHD)
Analysts' Ratings History for Cepheid (NASDAQ:CPHD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/22/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
9/12/2016Robert W. BairdDowngradeOutperform -> Neutral$53.00N/AView Rating Details
9/8/2016Citigroup Inc.DowngradeBuy -> Neutral$44.00 -> $53.00N/AView Rating Details
9/7/2016Barclays PLCBoost Price TargetEqual Weight$36.00 -> $52.00N/AView Rating Details
9/7/2016BTIG ResearchDowngradeBuy -> NeutralN/AView Rating Details
9/7/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
9/6/2016Craig HallumDowngradeBuy -> HoldN/AView Rating Details
9/6/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
9/6/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
8/17/2016Jefferies Group LLCBoost Price TargetHold$28.00 -> $34.00N/AView Rating Details
7/29/2016J P Morgan Chase & CoBoost Price TargetNeutral$32.00 -> $35.00N/AView Rating Details
6/15/2016Morgan StanleyInitiated CoverageEqual Weight$30.00N/AView Rating Details
4/1/2016Atlantic SecuritiesUpgradeNeutral -> OverweightN/AView Rating Details
3/28/2016WedbushLower Price TargetOutperform$58.00 -> $55.00N/AView Rating Details
2/3/2016Stifel NicolausLower Price TargetBuy$42.00 -> $38.00N/AView Rating Details
2/3/2016Leerink SwannReiterated RatingMarket Perform$39.00 -> $33.00N/AView Rating Details
1/6/2016Avondale PartnersInitiated CoverageOutperform$46.00N/AView Rating Details
12/2/2015Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
10/21/2015Evercore ISIUpgradeSell -> Hold$44.50 -> $32.50N/AView Rating Details
10/21/2015MizuhoLower Price TargetBuy$60.00 -> $42.00N/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Cepheid (NASDAQ:CPHD)
Earnings by Quarter for Cepheid (NASDAQ:CPHD)
Earnings History by Quarter for Cepheid (NASDAQ CPHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/28/2016Q216($0.14)$0.05$145.82 million$146.00 millionViewListenView Earnings Details
4/28/2016Q116$0.01$0.08$140.35 million$144.80 millionViewN/AView Earnings Details
2/2/2016Q415($0.20)($0.14)$146.95 million$147.00 millionViewN/AView Earnings Details
10/20/2015Q3($0.31)($0.13)$126.81 million$126.50 millionViewListenView Earnings Details
7/23/2015Q215($0.21)($0.06)$130.70 million$132.50 millionViewListenView Earnings Details
4/23/2015Q115($0.17)$0.06$125.50 million$132.60 millionViewN/AView Earnings Details
1/29/2015Q414($0.13)$0.11$125.34 million$131.50 millionViewN/AView Earnings Details
10/16/2014Q314($0.16)($0.10)$110.10 million$115.20 millionViewListenView Earnings Details
7/17/2014Q214($0.13)($0.10)$115.47 million$116.50 millionViewN/AView Earnings Details
4/17/2014Q114($0.19)($0.13)$104.90 million$106.90 millionViewN/AView Earnings Details
1/30/2014Q413($0.10)($0.07)$102.17 million$113.30 millionViewN/AView Earnings Details
7/18/2013Q2 2013$0.04$0.02$92.57 million$96.00 millionViewN/AView Earnings Details
4/18/2013Q1 2013$0.10$0.11$89.12 million$91.90 millionViewN/AView Earnings Details
1/24/2013Q4 2012$0.11$0.20$92.87 million$92.40 millionViewN/AView Earnings Details
10/18/2012($0.07)($0.32)ViewN/AView Earnings Details
7/19/2012$0.11$0.11ViewN/AView Earnings Details
4/19/2012($0.01)($0.08)ViewN/AView Earnings Details
1/26/2012($0.02)($0.03)ViewN/AView Earnings Details
10/20/2011$0.02$0.03ViewN/AView Earnings Details
7/21/2011($0.01)$0.03ViewN/AView Earnings Details
4/20/2011($0.01)$0.01ViewN/AView Earnings Details
1/27/2011($0.02)$0.02ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cepheid (NASDAQ:CPHD)
Current Year EPS Consensus Estimate: $0.33 EPS
Next Year EPS Consensus Estimate: $0.99 EPS


Dividend History for Cepheid (NASDAQ:CPHD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cepheid (NASDAQ:CPHD)
Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 95.75%
Insider Trades by Quarter for Cepheid (NASDAQ:CPHD)
Institutional Ownership by Quarter for Cepheid (NASDAQ:CPHD)
Insider Trades by Quarter for Cepheid (NASDAQ:CPHD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/17/2016Scott A CampbellVPSell287$36.16$10,377.92View SEC Filing  
8/4/2016Scott A CampbellVPSell746$36.71$27,385.66View SEC Filing  
5/3/2016Scott A CampbellVPSell2,058$27.90$57,418.20View SEC Filing  
5/2/2016Peter V FarrellEVPSell390$28.90$11,271.00View SEC Filing  
4/28/2016Peter V FarrellEVPSell390$36.30$14,157.00View SEC Filing  
4/25/2016John L BishopCEOSell110,000$35.50$3,905,000.00View SEC Filing  
3/10/2016Peter V FarrellEVPSell393$33.01$12,972.93View SEC Filing  
2/8/2016Warren C. Kocmond, Jr.COOSell292$28.53$8,330.76View SEC Filing  
2/1/2016Warren C. Kocmond, Jr.COOSell351$28.44$9,982.44View SEC Filing  
1/22/2016Warren C. Kocmond, Jr.COOSell157$33.16$5,206.12View SEC Filing  
12/10/2015Peter V. FarrellEVPSell394$31.67$12,477.98View SEC Filing  
11/20/2015Robert J EastonDirectorSell3,206$36.02$115,480.12View SEC Filing  
11/17/2015Robert J EastonDirectorSell2,724$34.84$94,904.16View SEC Filing  
11/12/2015Robert J EastonDirectorSell2,556$35.01$89,485.56View SEC Filing  
10/30/2015Peter V. FarrellEVPSell1,560$33.89$52,868.40View SEC Filing  
8/27/2015Peter V. FarrellEVPSell1,577$48.67$76,752.59View SEC Filing  
8/25/2015Cristina KepnerDirectorBuy10,000$47.78$477,800.00View SEC Filing  
6/26/2015Warren C Kocmond JrCOOSell9,375$61.52$576,750.00View SEC Filing  
4/29/2015Thomas L GutshallDirectorSell1,800$56.62$101,916.00View SEC Filing  
4/21/2015Joseph H SmithEVPSell91,866$54.51$5,007,615.66View SEC Filing  
4/20/2015John L BishopCEOSell100,000$55.20$5,520,000.00View SEC Filing  
2/25/2015Hollings RentonDirectorSell9,375$57.76$541,500.00View SEC Filing  
2/13/2015Dean O MortonDirectorSell12,500$58.51$731,375.00View SEC Filing  
2/3/2015Thomas D BrownDirectorSell12,500$56.29$703,625.00View SEC Filing  
1/30/2015Andrew MillerCFOSell6,677$57.64$384,862.28View SEC Filing  
1/12/2015Andrew MillerCFOSell11,719$56.65$663,881.35View SEC Filing  
1/12/2015David H PersingEVPSell5,000$56.90$284,500.00View SEC Filing  
1/12/2015Warren C Kocmond JrCOOSell4,688$57.00$267,216.00View SEC Filing  
1/5/2015Andrew MillerCFOSell2,250$54.95$123,637.50View SEC Filing  
1/5/2015Kerry FlomEVPSell8,694$54.21$471,301.74View SEC Filing  
11/19/2014Dean O MortonDirectorSell11,849$52.96$627,523.04View SEC Filing  
11/7/2014Hollings RentonDirectorSell9,375$51.07$478,781.25View SEC Filing  
10/31/2014Andrew MillerCFOSell12,167$53.84$655,071.28View SEC Filing  
10/31/2014David H PersingEVPSell20,000$53.34$1,066,800.00View SEC Filing  
10/31/2014Dean O MortonDirectorSell7,500$52.64$394,800.00View SEC Filing  
10/29/2014Kerry FlomEVPSell7,077$51.36$363,474.72View SEC Filing  
10/29/2014Thomas L GutshallDirectorSell12,500$51.63$645,375.00View SEC Filing  
10/28/2014David H PersingEVPSell15,000$51.51$772,650.00View SEC Filing  
10/3/2014Kerry FlomEVPSell1,271$44.52$56,584.92View SEC Filing  
8/7/2014Warren C Kocmond JrEVPSell324$38.69$12,535.56View SEC Filing  
7/14/2014Kerry FlomEVPSell2,812$49.72$139,812.64View SEC Filing  
7/3/2014Kerry FlomEVPSell1,282$48.97$62,779.54View SEC Filing  
5/29/2014Kerry FlomEVPSell4,265$45.49$194,014.85View SEC Filing  
5/22/2014Warren C Kocmond JrEVPSell1,300$42.38$55,094.00View SEC Filing  
4/29/2014Kerry FlomEVPSell2,660$42.38$112,730.80View SEC Filing  
4/25/2014John BishopCEOSell107,651$43.93$4,729,108.43View SEC Filing  
4/22/2014John BishopCEOSell42,349$46.11$1,952,712.39View SEC Filing  
4/22/2014Robert EastonDirectorSell12,500$45.59$569,875.00View SEC Filing  
4/3/2014Kerry FlomEVPSell1,621$51.55$83,562.55View SEC Filing  
4/1/2014Andrew MillerCFOSell4,688$52.78$247,432.64View SEC Filing  
3/13/2014Andrew MillerCFOSell17,265$55.55$959,070.75View SEC Filing  
1/31/2014Andrew MillerCFOSell63,375$53.10$3,365,212.50View SEC Filing  
1/31/2014John BishopCEOSell150,000$50.67$7,600,500.00View SEC Filing  
1/31/2014Joseph SmithEVPSell50,000$51.15$2,557,500.00View SEC Filing  
1/3/2014Kerry FlomEVPSell6,357$45.66$290,260.62View SEC Filing  
1/2/2014Andrew MillerCFOSell2,437$45.92$111,907.04View SEC Filing  
12/23/2013Kerry FlomEVPSell10,000$46.51$465,100.00View SEC Filing  
10/30/2013David H PersingVPSell5,000$41.35$206,750.00View SEC Filing  
10/29/2013Kerry FlomEVPSell2,660$40.50$107,730.00View SEC Filing  
10/24/2013Thomas L GutshallDirectorSell3,000$40.07$120,210.00View SEC Filing  
10/18/2013David H PersingVPSell20,000$40.59$811,800.00View SEC Filing  
9/24/2013Thomas GutshallDirectorSell3,000$38.97$116,910.00View SEC Filing  
9/18/2013David PersingVPSell5,000$39.34$196,700.00View SEC Filing  
9/16/2013David PersingVPSell5,000$38.95$194,750.00View SEC Filing  
9/6/2013David H PersingVPSell20,000$37.99$759,800.00View SEC Filing  
8/30/2013David PersingVPSell5,129$36.62$187,823.98View SEC Filing  
8/26/2013Thomas GutshallDirectorSell3,000$36.38$109,140.00View SEC Filing  
8/21/2013Robert EastonDirectorSell7,500$35.01$262,575.00View SEC Filing  
7/24/2013Thomas L GutshallDirectorSell3,000$34.18$102,540.00View SEC Filing  
6/24/2013Thomas L GutshallDirectorSell3,000$32.91$98,730.00View SEC Filing  
5/28/2013Andrew MillerCFOSell22,468$38.51$865,242.68View SEC Filing  
5/24/2013Thomas L GutshallDirectorSell3,000$37.90$113,700.00View SEC Filing  
5/13/2013Kerry FlomEVPSell6,832$39.76$271,640.32View SEC Filing  
3/25/2013Thomas L GutshallDirectorSell3,000$38.28$114,840.00View SEC Filing  
2/4/2013Joseph H SmithEVPSell38,400$36.20$1,390,080.00View SEC Filing  
12/24/2012Thomas L GutshallDirectorSell3,000$33.06$99,180.00View SEC Filing  
11/26/2012Thomas L GutshallDirectorSell7,778$31.94$248,429.32View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Cepheid (NASDAQ:CPHD)
Latest Headlines for Cepheid (NASDAQ:CPHD)
seekingalpha.com logoCepheid expands respiratory disease portfolio with Xpert Xpress Strep A
seekingalpha.com - October 5 at 11:03 AM
americanbankingnews.com logoHead to Head Contrast: Cepheid (CPHD) vs. Varex Imaging (VREX)
www.americanbankingnews.com - September 9 at 4:06 AM
americanbankingnews.com logoContrasting Cepheid (CPHD) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 5 at 7:06 AM
americanbankingnews.com logoFinancial Review: Sequenom (SQNM) & Cepheid (CPHD)
www.americanbankingnews.com - August 1 at 8:30 PM
americanbankingnews.com logoContrasting Cepheid (NASDAQ:CPHD) and Myriad Genetics (MYGN)
www.americanbankingnews.com - July 30 at 7:27 AM
americanbankingnews.com logoComparing Myriad Genetics (MYGN) & Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 29 at 10:11 AM
americanbankingnews.com logoReviewing Cepheid (CPHD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 28 at 7:14 AM
americanbankingnews.com logoHead-To-Head Comparison: Myriad Genetics (MYGN) vs. Cepheid (CPHD)
www.americanbankingnews.com - July 22 at 7:36 AM
americanbankingnews.com logoHead to Head Survey: Cepheid (NASDAQ:CPHD) versus Myriad Genetics (MYGN)
www.americanbankingnews.com - July 21 at 8:04 AM
americanbankingnews.com logoAnalyzing Cepheid (CPHD) and Alphatec Holdings (ATEC)
www.americanbankingnews.com - July 20 at 9:42 AM
americanbankingnews.com logoComparing Myriad Genetics (MYGN) & Cepheid (CPHD)
www.americanbankingnews.com - July 14 at 8:36 AM
americanbankingnews.com logoHead-To-Head Comparison: Alphatec Holdings (ATEC) vs. Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 12 at 8:16 AM
bizjournals.com logoThese drug and medical device companies made the most payments to L.A. hospitals
www.bizjournals.com - March 3 at 9:29 PM
nasdaq.com logoIntegrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV, Omega ...
www.nasdaq.com - January 19 at 10:48 PM
seekingalpha.com logoDanaher initiates 2017 outlook
seekingalpha.com - December 15 at 4:53 PM
biz.yahoo.com logoCEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or
biz.yahoo.com - November 7 at 11:02 PM
streetinsider.com logoDanaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition - StreetInsider.com
www.streetinsider.com - November 7 at 7:55 AM
biz.yahoo.com logoCEPHEID Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 3 at 9:56 PM
biz.yahoo.com logoCEPHEID Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 28 at 9:11 PM
nasdaq.com logoIWO, MSCC, AZPN, CPHD: Large Outflows Detected at ETF
www.nasdaq.com - October 25 at 9:37 PM
nasdaq.com logoCepheid Says Receives Regulatory Clearances In Proposed Acquisition By Danaher
www.nasdaq.com - October 24 at 4:16 PM
streetinsider.com logoCepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger
www.streetinsider.com - October 24 at 4:16 PM
streetinsider.com logoCepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger - StreetInsider.com
www.streetinsider.com - October 24 at 9:34 AM
biz.yahoo.com logoCEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - October 24 at 9:33 AM
nasdaq.com logoiShares Russell 2000 Growth ETF Experiences Big Outflow
www.nasdaq.com - October 14 at 4:15 PM



Cepheid (CPHD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.